Daily Stock Analysis, CPHR, Cipher Pharmaceuticals Inc, priceseries

Cipher Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.99
Close
2.99
High
2.99
Low
2.99
Previous Close
2.99
Daily Price Gain
0.00
YTD High
6.37
YTD High Date
Apr 15, 2016
YTD Low
2.55
YTD Low Date
Nov 14, 2016
YTD Price Change
-1.55
YTD Gain
-34.14%
52 Week High
6.37
52 Week High Date
Apr 15, 2016
52 Week Low
2.55
52 Week Low Date
Nov 14, 2016
52 Week Price Change
-1.68
52 Week Gain
-35.97%
Company Information
Stock Symbol
CPHR
Exchange
NasdaqGM
Company URL
http://www.cipherpharma.com
Company Phone
905-602-5840
CEO
Shawn Patrick O'Brien
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001358575
About

Cipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in Canada and the United States.

Description

Cipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in Canada and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. The company also provides SITAVIG, a buccal tablet comprising 50 mg of acyclovir for the treatment of herpes labialis; NUVAIL, a polymer solution for managing the signs and symptoms of nail dystrophy; and BIONECT, a topical hyaluronic acid for the treatment of signs and symptoms of skin irritation. In addition, it offers BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions, such as plaque psoriasis; Dermadexin, a topical barrier-repair cream for the treatment of seborrheic dermatitis; and Pruridexin, a topical cream for the treatment of chronic pruritis. Further, the company is developing Ozenoxacin that has completed Phase III clinical trials to treat adult and paediatric patients with impetigo; ASF-1096, a product candidate in Phase II that is being investigated as a treatment for discoid lupus erythematosus; and CF101, a novel chemical entity that has completed Phase II/III double-blind and placebo-controlled study to treat patients with moderate to severe plaque psoriasis, as well as Nanolipolee-007, a liposomal formulation of a plant-derived compound. Cipher Pharmaceuticals Inc. was founded in 2004 and is headquartered in Mississauga, Canada.